The distribution and fluconazole susceptibilities of Candida species isolated over a 5-year period were investigated. Susceptibilities were determined by using a new microtiter procedure and the National Committee for Clinical Laboratory Standards (NCCLS) proposed standard. The new method correlated well with the NCCLS proposed standard and gave very clear end points. Results indicate that there are species-related differences in MICs as reflected in the MICs for 90% of species tested. Candida albicans is most susceptible to fluconazole, while Candida glabrata is among the least susceptible. These findings coincided with the observation of a shift in distribution of yeast species recovered from blood cultures from 1987 to 1992. C. albicans was the predominant species (87%) in the pre-or early fluconazole years but decreased to only 31% of the isolates in 1992. Thus, Candida species for which MICs of fluconazole were higher have become more prominent in recent years. Significantly, throughout this period, MICs for each species did not change appreciably.
The incidence of serious fungal infections continues to increase. While amphotericin B was the only drug available for therapy in patients with serious fungal infections, susceptibility testing was considered unnecessary (3, 4) . With the recent availability of the newer azoles, however, this situation is likely to change (7) . To this end, collaborative efforts directed towards the standardization of in vitro antifungal susceptibility testing have produced a proposed National Committee for Clinical Laboratory Standards (NCCLS) standard for susceptibility testing of yeasts by broth macrodilution (5) . However, clinical laboratories more familiar with broth microdilution technology may find the proposed standard difficult to embrace.
The aims of this study were to evaluate a modified broth microdilution method (1) Table 1 ). The procedure used was a modification of that described by a The MIC resulting from the NCCLS method was either equal to (Same), one dilution tube greater than (+ 1), one dilution tube less than (-1), or more than one dilution tube greater than (>+ 1) the MIC of the microtiter method.
b The Candida spp. included C albicans (20 isolates), C. tropicalis (11 isolates), and C. krusei (10 isolates).
ensure even distribution of the inoculum. After incubation at 35°C for 24 h, the microtiter plate was removed from the incubator and shaken for 5 min (setting 50; Dynatech plate shaker), and the optical density of each well was read at 530 nm (model MR400 Dynatech plate reader). The MIC was considered to be that concentration of drug which allowed 25% or less growth than that of the control (1, 8) . C. albicans ATCC 14053 was used to test each new batch of microtiter plates and was included initially in every series of MICs tested. In all cases, the MIC for this strain was s0.125 or 0.25 ,ug/ml, predominantly 0.25 ,ug/ml. For future quality control purposes, the use of a Candida strain for which the MIC is higher (0.25 to 0.5 ,ug/ml) should ensure growth at the end point. The growth on blood agar (or Schaedler's agar) prior to susceptibility testing effectively resolved the tailing problem seen previously with azoles (4, 8) . When it occurred, growth decreased dramatically to give a clear end point rather than gradually declining with a tailing end point through a number of dilution wells, as seen previously. This effect may, at least in part, be related to the growth phase of these microorganisms when they are exposed to azole (2) , an important factor in antibacterial susceptibility testing. Candida species grow well on blood agar; however, C. glabrata has special growth requirements (6) . All strains of this fungus grew well on Schaedler's agar. To confirm that prior growth on this medium, which contains yeast extract, did not interfere with end point determination, four strains of C. glabrata were grown on both Schaedler's agar and in RPMI medium prior to susceptibility testing by the microtiter method. In three cases, the MICs for the strains were identical, and in one case, there was a single dilution difference. Any carryover of yeast extract would likely result in a much greater discrepancy between the two groups.
The MICs for 50 and 90% of the strains (MlC50 and MIC90, respectively) obtained before and after the institutional use of fluconazole are shown in Table 1 . The MIC50 and MIC90 of fluconazole for C. albicans appear to be less than those of other species.
A total of 57 Candida strains were also tested by the NCCLS-recommended method. The results are shown in Table 2 . For most Candida species tested, the NCCLS method gave an MIC equal to or one tube greater than that of the 
